Oncology
Nitroreductase mutants improve cell sensitivity to chemotherapy
Published in Cancer Weekly, November 11th, 2003
According to recent research from England, "Escherichia coli nitroreductase (NTR) activates the prodrug CB1954 to a cytotoxic derivative, allowing selective sensitization of NTR-expressing cells or tumors to the prodrug. This is one of several enzyme-prodrug combinations that are under development for cancer gene therapy, and the system has now entered clinical trials. Enhancing the catalytic efficiency of NTR for CB1954 could improve its therapeutic potential."
"From the crystal structure of an enzyme-ligand complex, we identified nine amino acid residues within the active site...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-11-11)
More Articles from Cancer Weekly
- Oncogenesis
Better model of cancer development sheds light on potential angiogenesis target - Prostate Cancer
Hormones increase side effects, complicate treatment decision for patients - Brain Cancer
Blocking expression of gene reduces invasion of deadly tumor cells - Breast Cancer
Exercise, healthy weight delay cancer among women with highest genetic risk - Breast Cancer
Micromechanics theory provides powerful tool for diagnosis of breast cancer - Acute Lymphoblastic Leukemia
Therapy overcomes differences in outcome between black, white children - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
